UPDATE: Roth Capital On Viking Therapeutics Buy Rating: Firm Highlights Continued Clinical Development Of VK0214 Treatment For X-ALD With Promising Phase 1a Data Leading Continuation Into Phase 1b Trials Attempting To Duplicate Results